# US 2021/0277145 A1 · Methods and pharmaceutical compositions for increasing endogenous protein level

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277145 A1
- Document ID: US20210277145A1
- Status: Published application
- Kind: A1
- Application number: 16/461,634
- Filed: 2017-11-16
- Published: 2021-09-09
- Earliest claimed: 2016-11-17
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite Paris-Sud
- Applicants: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite Paris-Sud
- Inventors: Peter LENTING; Gabriel AYME; Olivier CHRISTOPHE; Charlotte KAWECKI; Cecile DENIS
- Web page: https://patentgrep.com/patent/US20210277145A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 16/38: against protease inhibitors of peptide structure
- C07K 16/36: against blood coagulation factors
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/31: multispecific
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2319/00: Fusion polypeptide
- C07K 2319/31: fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a peptide comprising the amino acid sequence QGLIGDIALPRWGALWGDSV (SEQ ID NO: 1). Inventors have tested in wild-type mice a single domain antibody directed against VWF and tagged with an albumin-binding peptide. After giving a single dose intravenously (50 microgram/mouse), VWF levels were increased 8-15 fold for at least 7 days, knowing that the half-life of VWF is about 2-3 hours in a mouse. Moreover, intravenous administration of VWF together with a sdAb fused to an albumin-binding peptide resulted in detectable levels of VWF at 48 and 72 hours after injection, whereas no VWF could be detected when injected in the absence of such sdAb fused to an albumin-binding peptide. Thus, these results show a very long-lasting effect of this new approach.

## Claims

### Claim 1

A peptide comprising the amino acid sequence QGLIGDIALPRWGALWGDSV (SEQ ID NO: 1).

### Claim 2

A nucleic acid encoding an amino acid sequence comprising SEQ ID NO: 1.

### Claim 3 (depends on 2)

An expression vector comprising the nucleic acid according to claim 2.

### Claim 4 (depends on 3)

A host cell comprising the expression vector according to claim 3.

### Claim 5 (depends on 1)

A drug conjugate comprising the peptide according to claim 1 linked to a heterologous moiety.

### Claim 6 (depends on 17)

The drug conjugate according to claim 17 wherein the heterologous polypeptide is an isolated single domain antibody.

### Claim 7 (depends on 1)

The drug conjugate according to claim 1, wherein the peptide of claim 1 is fused to an isolated single domain antibody to form a fusion protein.

### Claim 8 (depends on 6)

The drug conjugate according to claim 6, wherein the isolated single domain antibody is directed against at least one endogenous protein selected from the group consisting of: Von Willebrand factor, Fibrinogen, Factor II (prothrombin), Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, Factor XII, Factor XIII, Protein C, Protein S, Protein Z, Protein Z-inhibitor, Tissue factor pathway inhibitor (TFPI), α1-antitrypsin inhibitor, Thrombin Activatable Fibrinolysis Inhibitor (TAFI)/carboxypeptidase B2, Antithrombin, α2-antiplasmin, Plasmin Activator Inhibitor-1 (PAI-1), Plasminogen, tissue plasminogen activator (tPA), urinary plasminogen activator (uPA), ADAMTS13, Complement protein C2, Complement protein C3, Complement protein C4, Complement protein C6, Complement factor H, Complement factor 1, Properdin, Ceruloplasmin, Kininogen, Thrombopoietin, Erytropoeitin, Soluble Mannose-binding lectin, Interferon-α, Interferon-β, Interferon-γ, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Keratinocyte growth factor, Interleukin-2, Interleukin-6, Interleukin-7, Interleukin-10, Interleukin-11, Interleukin-12, Interleukin-15, Interleukin-21, Growth hormone-releasing hormone and Hyaluronidase.

### Claim 9 (depends on 6)

The drug conjugate according to claim 6, wherein the isolated single domain antibody comprises:
i) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:2, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:3 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:4;
ii) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:7, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:8 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:9;
iii) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:12, a CDR2 having at least 700/of identity with a sequence set forth as SEQ ID NO:13 and a CDR3 having at least 70/o of identity with a sequence set forth as SEQ ID NO:14;
iv) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:17, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:18 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:19;
v) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:21, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:22 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:23;
vi) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:25, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:26 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:27;
vii) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:29, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:30 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:31;
viii) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:33, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:34 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:35;
ix) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:37, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:38 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:39;
x) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:41, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:42 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:43;
xi) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:54, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:55 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:56;
xii) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:59, a CDR2 having at least 70%/0 of identity with a sequence set forth as SEQ ID NO:60 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:61:
xiii) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:64, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:65 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:66;
xiv) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:69, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:70 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:71;
xv) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:74, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:75 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:76;
xvi) a CDR1 having at least 70% of identity with 1 sequence set forth as SEQ ID NO:79, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:80 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:81;
xvii) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:84, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:85 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:86; or
xviii) a CDR1 having at least 70% of identity with a sequence set forth as SEQ ID NO:89, a CDR2 having at least 70% of identity with a sequence set forth as SEQ ID NO:90 and a CDR3 having at least 70% of identity with a sequence set forth as SEQ ID NO:91.

### Claim 10 (depends on 6)

The drug conjugate according to claim 6, wherein the isolated single domain antibody comprises:
i) a CDR1 having a sequence set forth as SEQ ID NO:2, a CDR2 having a sequence set forth as SEQ ID NO:3 and a CDR3 having a sequence set forth as SEQ ID NO:4;
ii) a CDR1 having a sequence set forth as SEQ ID NO:7, a CDR2 having a sequence set forth as SEQ ID NO:8 and a CDR3 having a sequence set forth as SEQ ID NO:9;
iii) a CDR1 having a sequence set forth as SEQ ID NO:12, a CDR2 having a sequence set forth as SEQ ID NO:13 and a CDR3 having a sequence set forth as SEQ ID NO:14;
iv) a CDR1 having a sequence set forth as SEQ ID NO:17, a CDR2 having a sequence set forth as SEQ ID NO:18 and a CDR3 a sequence set forth as SEQ ID NO:19;
v) a CDR1 having a sequence set forth as SEQ ID NO:21, a CDR2 having g sequence set forth as SEQ ID NO:22 and a CDR3 having a sequence set forth as SEQ ID NO:23;
vi) a CDR1 having a sequence set forth as SEQ ID NO:25, a CDR2 having a sequence set forth as SEQ ID NO:26 and a CDR3 having a sequence set forth as SEQ ID NO:27;
vii) a CDR1 having a sequence set forth as SEQ ID NO:29, a CDR2 having a sequence set forth as SEQ ID NO:30 and a CDR3 having a sequence set forth as SEQ ID NO:31;
viii) a CDR1 having a sequence set forth as SEQ ID NO:33, a CDR2 having a sequence set forth as SEQ ID NO:34 and a CDR3 having a sequence set forth as SEQ ID NO:35;
ix) a CDR1 having a sequence set forth as SEQ ID NO:37, a CDR2 having a sequence set forth as SEQ ID NO:38 and a CDR3 having a sequence set forth as SEQ ID NO:39;
x) a CDR1 having a sequence set forth as SEQ ID NO:41, a CDR2 having a sequence set forth as SEQ ID NO:42 and a CDR3 having a sequence set forth as SEQ ID NO:43;
xi) a CDR1 having a sequence set forth as SEQ ID NO:54, a CDR2 having a sequence set forth as SEQ ID NO:55 and a CDR3 having a sequence set forth as SEQ ID NO:56;
xii) a CDR1 having a sequence set forth as SEQ ID NO:59, a CDR2 having a sequence set forth as SEQ ID NO:60 and a CDR3 having a sequence set forth as SEQ ID NO:61;
xiii) a CDR1 having a sequence set forth as SEQ ID NO:64, a CDR2 having a sequence set forth as SEQ ID NO:65 and a CDR3 having a sequence set forth as SEQ ID NO:66;
xiv) a CDR1 having a sequence set forth as SEQ ID NO:69, a CDR2 having a sequence set forth as SEQ ID NO:70 and a CDR3 having a sequence set forth as SEQ ID NO:71;
xv) a CDR1 having a sequence set forth as SEQ ID NO:74, a CDR2 having a sequence set forth as SEQ ID NO:75 and a CDR3 having a sequence set forth as SEQ ID NO:76;
xvi) a CDR1 having a sequence set forth as SEQ ID NO:79, a CDR2 having a sequence set forth as SEQ ID NO:80 and a CDR3 having a sequence set forth as SEQ ID NO:81;
xvii) a CDR1 having a sequence set forth as SEQ ID NO:84, a CDR2 having g sequence set forth as SEQ ID NO:85 and a CDR3 having a sequence set forth as SEQ ID NO:86; or
xviii) a CDR1 having a sequence set forth as SEQ ID NO:89, a CDR2 having a sequence set forth as SEQ ID NO:90 and a CDR3 having a sequence set forth as SEQ ID NO:91.

### Claim 11 (depends on 6)

The drug conjugate according to, claim 6, wherein the isolated single domain antibody is:
i) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO:5;
ii) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO:10;
iii) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO:15;
iv) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 20;
v) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 24;
vi) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 28;
vii) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 32;
viii) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 36;
ix) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 40;
x) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 44;
xi) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 57;
xii) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO; 62;
xiii) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 67;
xiv) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEO ID NO: 72;
xv) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 77;
xvi) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 82;
xvii) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, %, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 87; or
xviii) an isolated single domain antibody having at least 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% of identity with the sequence set forth as SEQ ID NO: 92.

### Claim 12 (depends on 6)

The drug conjugate according to claim 6, wherein the isolated single domain antibody is or comprises:
i) an isolated single domain antibody having a sequence set forth as SEQ ID NO:5;
ii) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 10;
iii) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 15;
iv) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 20
v) an isolated single domain antibody having a sequence set forth as SEQ ID NO:24;
vi) an isolated single domain antibody having a sequence set forth as SEQ ID NO:28;
vii) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 32;
viii) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 36;
ix) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 40;
x) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 44;
xi) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 57;
xii) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 62;
xiii) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 67;
xiv) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 72;
xv) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 77;
xvi) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 82;
xvii) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 87; or
xviii) an isolated single domain antibody having a sequence set forth as SEQ ID NO: 92.

### Claim 13 (depends on 6)

The drug conjugate according to claim 6, wherein said isolated single domain antibody is fused to a peptide comprising the amino acid sequence OGLIGDIALPRWGALWGDSV (SEQ ID NO: 1) and a sequence set forth as SEQ ID NO: 6; SEQ ID NO: 11; SEQ ID NO: 16; SEQ ID NO: 49; SEQ ID NO: 58, SEQ ID NO: 63, SEQ ID NO: 68, SEQ ID NO: 73: SEQ ID NO: 78; SEQ ID NO: 83, SEQ ID NO: 88 or SEQ ID NO: 93.

### Claim 14 (depends on 6)

The drug conjugate according to claim 6, wherein the isolated single domain antibody comprises: i) the sequences KB-AT-002 and one KB-AT-003 having at least 70% sequence identity with a sequence set forth as SEQ ID NO: 45; ii) the sequences KB-AT-001 and KB-AT-002 having at least 70% sequence identity with a sequence set forth as SEQ ID NO: 46; iii) the sequences KB-AT-001 and KB-AT-003 having at least 70% sequence identity with a sequence set forth as SEQ ID NO: 47; iv) the sequences KB-AT-001 and KB-AT-005 having at least 70% sequence identity with a sequence set forth as SEQ ID NO: 48; v) the two sequences of KB-AT-001 and one sequence of KB-AT-002, having at least 70% sequence identity with a sequence set forth as SEQ ID NO: 50; vi) the two sequences of KB-AT-001 and KB-AT-003 having at least 70% sequence identity with a sequence set forth as SEQ ID NO: 51; vii) the two sequences of KB-AT-001 and KB-AT-005 having at least 70% sequence identity with a sequence set forth as SEQ ID NO: 52 or two sequences of KB-AT-001, one of KB-AT-002 sequence and one sequence of KB-AT-003, having at least 70% sequence identity with a sequence set forth as SEQ ID NO: 53.

### Claim 15 (depends on 5)

A method of extending or increasing the half-life and the level of an endogenous protein in a subject comprising a step of administering to the subject the drug conjugate according to claim 5 wherein the drug conjugate is or is not inserted into a vector.

### Claim 16 (depends on 5)

A method of treating a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of the drug conjugate according to claim 5.

### Claim 17 (depends on 5)

The drug conjugate of claim 5, wherein the heterologous moiety is a heterologous polypeptide.
